Forest Laboratories, Inc. and Almirall to Present Data from Studies of Aclidinium Bromide in Chronic Obstructive Pulmonary Disease (COPD) and LAS100977 in Asthma

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) and Almirall, S.A. (ALM.MC) today announced that they are presenting data from several studies of two investigational inhaled respiratory compounds at the annual American Thoracic Society International Conference taking place in New Orleans May 14-19, 2010. Data on aclidinium bromide, an inhaled muscarinic antagonist, which is in Phase III development for COPD, and LAS100977, a long-acting beta 2-agonist, in Phase II development for asthma, will be presented in 11 separate posters. In addition, 3 posters reporting data on the GenuairĀ® inhaler, which is used to administer the compounds, will be presented.

Back to news